Status:
TERMINATED
Phase II Study of TAS-106 to Treat Head and Neck Cancer
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
Eligibility Criteria
Inclusion
- Age 18 ≤ years old at study entry
- Histologically confirmed head and neck carcinoma
- Received prior platinum based regimen and developed disease progression or recurrence
- Measurable disease according to RECIST guidelines
Exclusion
- Radiological or clinical evidence of brain involvement or leptomeningeal disease
- ≥ grade 2 peripheral neuropathy
- History of another malignancy
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00737360
Start Date
August 1 2008
End Date
February 1 2012
Last Update
September 5 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Orleans Street, Baltimore, Maryland, United States, 21231
2
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
3
The Chinese University of Hong Kong, Prince of Wales Hospital
Shatin, Hksar, Hong Kong
4
National University Hospital
Lower Kent Ridge Road, Singapore, 119074